{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T23:52:33Z","timestamp":1777593153150,"version":"3.51.4"},"reference-count":57,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,8,31]],"date-time":"2023-08-31T00:00:00Z","timestamp":1693440000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec><jats:title>Purpose<\/jats:title><jats:p>This systematic review was performed to assess the potential influence of medication-induced salivary changes on the development of medication-related osteonecrosis of the jaw (MRONJ).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>An electronic search was conducted using PubMed, Web of Science, Cochrane, and Embase databases for articles published up to June 2023. A risk of bias assessment was performed according to the modified Newcastle\u2013Ottawa Scale (NOS). Due to the heterogeneity of the selected studies in relation to the type of medications and outcomes evaluated, a meta-analysis could not be performed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The initial search revealed 765 studies. Only 10 articles were found to be eligible based on the inclusion criteria that reported on the impact of salivary changes on MRONJ following the administration of different medications. A total of 272 cases of MRONJ (35% women, 32% men, and 32% with no gender reported) with a mean age of 66 years at the time of diagnosis were included. Patients administered with bisphosphonates, steroids, chemotherapy, thalidomide, interferon, and hormone therapy had a significantly higher association between decreased salivary flow and MRONJ occurrence. In addition, bisphosphonates, denosumab, and other bone-modifying agents showed a significantly higher risk of developing MRONJ owing to the changes in salivary microbiome profiles, cytokine profiles, interleukins, hypotaurine, and binding proteins.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The reduction in salivary flow and changes in the concentration of salivary proteins were associated with the development of MRONJ. However, due to the availability of limited evidence, the findings of the review should be interpreted with caution.<\/jats:p><\/jats:sec><jats:sec><jats:title>Prospero review registration<\/jats:title><jats:p><jats:ext-link>https:\/\/www.crd.york.ac.uk\/PROSPERO\/<\/jats:ext-link>, identifier: CRD42022327645.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fmed.2023.1164051","type":"journal-article","created":{"date-parts":[[2023,8,31]],"date-time":"2023-08-31T16:10:07Z","timestamp":1693498207000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Are medication-induced salivary changes the culprit of osteonecrosis of the jaw? A systematic review"],"prefix":"10.3389","volume":"10","author":[{"given":"Isti Rahayu","family":"Suryani","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iraj","family":"Ahmadzai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Minh Ton","family":"That","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sohaib","family":"Shujaat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reinhilde","family":"Jacobs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2023,8,31]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.joms.2021.09.021","article-title":"Medication-related osteonecrosis of the jaw (MRONJ)","volume":"80","author":"Bedogni","year":"2022","journal-title":"J Oral Maxillof Surg."},{"key":"B2","doi-asserted-by":"publisher","first-page":"97","DOI":"10.4103\/2231-0762.178742","article-title":"Medication-related osteonecrosis of the jaw: Clinical and practical guidelines","volume":"6","author":"Rosella","year":"2016","journal-title":"J Int Soc Prev Community Dent."},{"key":"B3","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.oooo.2014.09.009","article-title":"Adverse drug events in the oral cavity","volume":"119","author":"Yuan","year":"2015","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1111\/j.1468-3083.2008.02637.x","article-title":"Oral manifestations of adverse drug reactions: guidelines","volume":"22","author":"Femiano","year":"2008","journal-title":"J Eur Acad Dermatol Venereol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/j.jcms.2011.05.003","article-title":"Bisphosphonate-related osteonecrosis of the jaws\u2013Characteristics, risk factors, clinical features, localization and impact on oncological treatment","volume":"40","author":"Otto","year":"2012","journal-title":"J Cranio-Maxillofacial Surg."},{"key":"B6","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/jbmr.2405","article-title":"Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus","volume":"30","author":"Khan","year":"2015","journal-title":"J Bone Miner Res."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.5037\/jomr.2010.1203","article-title":"Bisphosphonate-related osteonecrosis of the jaw bone: radiological pattern and the potential role of CBCT in early diagnosis","volume":"1","author":"Olutayo","year":"2010","journal-title":"J Oral Maxillofac Res."},{"key":"B8","doi-asserted-by":"publisher","first-page":"2973","DOI":"10.1007\/s00784-020-03423-0","article-title":"Early imaging signs of the use of antiresorptive medication and MRONJ: a systematic review","volume":"24","author":"Moreno-Rabi\u00e9","year":"2020","journal-title":"Clin Oral Investig."},{"key":"B9","unstructured":"Why do some extraction sites develop medication- related osteonecrosis of the jaw and others do not? A within-patient study assessing radiographic predictors8798\n            Ga\u00eata-araujoH\n            LeiteAF\n            VasconcelosKDF\n            CoropciucR\n          34006074Int J Oral Implantol.142021"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/froh.2022.866871","article-title":"Oral complications in cancer patients\u2013medication-related osteonecrosis of the jaw (MRONJ)","volume":"3","author":"Migliorati","year":"2022","journal-title":"Front Oral Heal"},{"key":"B11","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1016\/j.joms.2022.02.008","article-title":"American association of oral and maxillofacial surgeons' position paper on medication-related osteonecrosis of the jaws\u20132022 update","volume":"80","author":"Ruggiero","year":"2022","journal-title":"J Oral Maxillofac Surg."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/ijerph17165998","article-title":"Medication-related osteonecrosis of jaws (MRONJ) prevention and diagnosis: Italian consensus update 2020","volume":"17","author":"Campisi","year":"2020","journal-title":"Int J Environ Res Public Health."},{"key":"B13","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1111\/odi.13294","article-title":"Alveolar bone histological necrosis observed prior to extractions in patients, who received bone-targeting agents","volume":"26","author":"Nicolatou-Galitis","year":"2020","journal-title":"Oral Dis."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1560175","DOI":"10.1155\/2017\/1560175","article-title":"Role of Periapical Diseases in Medication-Related Osteonecrosis of the Jaws","volume":"2017","author":"Rao","year":"2017","journal-title":"Biomed Res Int."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1871","DOI":"10.1002\/jbmr.379","article-title":"Periodontal disease and bisphosphonates induce osteonecrosis of the jaws in the rat","volume":"26","author":"Aghaloo","year":"2011","journal-title":"J Bone Miner Res."},{"key":"B16","doi-asserted-by":"publisher","first-page":"2143","DOI":"10.1007\/s00784-018-2655-z","article-title":"Microbial diversity in infections of patients with medication-related osteonecrosis of the jaw","volume":"23","author":"Zirk","year":"2019","journal-title":"Clin Oral Investig."},{"key":"B17","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1111\/odi.12708","article-title":"Risk factors for medication-related osteonecrosis of the jaws: A systematic review","volume":"24","author":"McGowan","year":"2018","journal-title":"Oral Dis."},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1016\/j.joms.2020.12.045","article-title":"Factors influencing severity of medication-related osteonecrosis of the jaw: a retrospective study","author":"Feng","year":"2021","journal-title":"J Oral Maxillofac Surg."},{"key":"B19","doi-asserted-by":"publisher","first-page":"6429","DOI":"10.1007\/s00520-022-06940-8","article-title":"The preventive care of medication-related osteonecrosis of the jaw (MRONJ): a position paper by Italian experts for dental hygienists","volume":"2022","author":"Mauceri","year":"2022","journal-title":"Support Care Cancer"},{"key":"B20","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1007\/s11914-018-0474-4","article-title":"Current understanding of the pathophysiology of osteonecrosis of the jaw","volume":"16","author":"Chang","year":"2018","journal-title":"Curr Osteoporos Rep."},{"key":"B21","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1016\/j.cden.2014.07.004","article-title":"Oral implications of polypharmacy in the elderly","volume":"58","author":"Singh","year":"2014","journal-title":"Dent Clin North Am."},{"key":"B22","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1007\/s00784-018-2337-x","article-title":"Salivary biomarkers for oral cancer and pre-cancer screening: a review","volume":"22","author":"Kaur","year":"2018","journal-title":"Clin Oral Investig."},{"key":"B23","doi-asserted-by":"publisher","first-page":"n160","DOI":"10.1136\/bmj.n160","article-title":"The PRISMA 2020 statement: An updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"B24","unstructured":"Newcastle-Ottawa Scale.\n            WellsG\n            SheaB\n            O'ConnellD\n            PetersonJ\n            WelchV\n            LososM\n          2007"},{"key":"B25","doi-asserted-by":"publisher","first-page":"e024655","DOI":"10.1136\/bmjopen-2018-024655","article-title":"Increased risk of bisphosphonate-related osteonecrosis of the jaw in patients with Sj\u00f6gren's syndrome: Nationwide population-based cohort study","volume":"9","author":"Liao","year":"2019","journal-title":"BMJ Open"},{"key":"B26","doi-asserted-by":"publisher","first-page":"e194","DOI":"10.4317\/medoral.18604","article-title":"Intravenous bisphosphonate-related osteonecrosis of the jaws: Influence of coadjuvant antineoplastic treatment and study of buccodental condition","volume":"18","author":"Margaix-Mu\u00f1oz","year":"2013","journal-title":"Med Oral Patol Oral Cir Bucal"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-020-80622-5","article-title":"Primary Sjogren syndrome increases the risk of bisphosphonate-related osteonecrosis of the jaw","volume":"11","author":"Kuo","year":"2021","journal-title":"Sci Rep."},{"key":"B28","doi-asserted-by":"publisher","first-page":"704722","DOI":"10.3389\/fonc.2021.704722","article-title":"Prospective observational study of bisphosphonate-related osteonecrosis of the jaw in multiple myeloma: microbiota profiling and cytokine expression","volume":"11","author":"Badros","year":"2021","journal-title":"Front Oncol"},{"key":"B29","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1111\/odi.14201","article-title":"Quantitative proteomics in medication-related osteonecrosis of the jaw: A proof-of-concept study","volume":"29","author":"Lorenzo-Pouso","year":"2022","journal-title":"Oral Dis April."},{"key":"B30","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.jcms.2020.01.005","article-title":"Saliva diagnostics in patients suffering from bisphosphonate-associated osteonecrosis of the jaw: Results of an observational study","volume":"48","author":"Stockmann","year":"2020","journal-title":"J Cranio-Maxillofacial Surg."},{"key":"B31","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1111\/odi.12150","article-title":"Interleukin-6 concentration changes in plasma and saliva in bisphosphonate-related osteonecrosis of the jaws","volume":"20","author":"Bagan","year":"2014","journal-title":"Oral Dis."},{"key":"B32","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1111\/jop.12021","article-title":"Bisphosphonates-related osteonecrosis of the jaws: A preliminary study of salivary interleukins","volume":"42","author":"Bagan","year":"2013","journal-title":"J Oral Pathol Med."},{"key":"B33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0220712","article-title":"Metabolomic profiling reveals salivary hypotaurine as a potential early detection marker for medication-related osteonecrosis of the jaw","volume":"14","author":"Yatsuoka","year":"2019","journal-title":"PLoS ONE."},{"key":"B34","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1634\/theoncologist.2011-0202","article-title":"Genomewide pharmacogenetics of bisphosphonate-induced osteonecrosis of the jaw: the role of RBMS3","volume":"17","author":"Nicoletti","year":"2012","journal-title":"Oncologist."},{"key":"B35","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1038\/ijos.2016.38","article-title":"Saliva in the diagnosis of diseases","volume":"8","author":"Zhang","year":"2016","journal-title":"Int J Oral Sci."},{"key":"B36","doi-asserted-by":"publisher","first-page":"5847429","DOI":"10.1155\/2020\/5847429","article-title":"Combined administration of bisphosphonates, chemotherapeutic agents, and\/or targeted drugs increases the risk for stage 3 medication-related osteonecrosis of the jaw: a 4-year retrospective study","volume":"2020","author":"Zhou","year":"2020","journal-title":"Biomed Res Int"},{"key":"B37","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1016\/j.tripleo.2008.04.003","article-title":"Oral mucosal lesions, microbial changes, and taste disturbances induced by adjuvant chemotherapy in breast cancer patients","volume":"106","author":"Jensen","year":"2008","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol Endod."},{"key":"B38","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1016\/j.tripleo.2009.11.015","article-title":"Molecular methodology to assess the impact of cancer chemotherapy on the oral bacterial flora: a pilot study","volume":"109","author":"Nape\u00f1as","year":"2010","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol Endod."},{"key":"B39","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.3390\/medicina59061073","article-title":"A Study of Oral Health Parameters and the Properties and Composition of Saliva in Oncological Patients with and without Medication-Related Osteonecrosis of the Jaw Who Take Bisphosphonates","volume":"59","author":"Sobczak-Jaskow","year":"2023","journal-title":"Medicina (Kaunas)"},{"key":"B40","doi-asserted-by":"publisher","first-page":"8376979","DOI":"10.1155\/2016\/8376979","article-title":"Is GERD a factor in osteonecrosis of the jaw? Evidence of pathology linked to G6PD deficiency and sulfomucins","volume":"2016","author":"Seneff","year":"2016","journal-title":"Dis Markers."},{"key":"B41","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1080\/00016357.2022.2069282","article-title":"Prevalence of dry mouth in adult patients in primary health care","volume":"80","author":"Adolfsson","year":"2022","journal-title":"Acta Odontol Scand"},{"key":"B42","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1034\/j.1601-0825.2003.03967.x","article-title":"Drug effects on salivary glands: dry mouth","volume":"9","author":"Scully","year":"2003","journal-title":"Oral Dis."},{"key":"B43","doi-asserted-by":"publisher","first-page":"15","DOI":"10.4103\/0975-8844.113684","article-title":"Adverse affects of drugs on saliva and salivary glands","volume":"5","author":"Vinayak","year":"2013","journal-title":"J Orofac Sci."},{"key":"B44","doi-asserted-by":"publisher","first-page":"2976","DOI":"10.3390\/jcm12082976","article-title":"Association between Hyperglycemia and Medication-Related Osteonecrosis of the Jaw (MRONJ)","volume":"12","author":"Kammerhofer","year":"2023","journal-title":"J Clin Med"},{"key":"B45","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1177\/0022034514560768","article-title":"Diabetes as a risk factor for medication-related osteonecrosis of the jaw","volume":"94","author":"Peer","year":"2015","journal-title":"J Dent Res."},{"key":"B46","doi-asserted-by":"publisher","first-page":"206","DOI":"10.5125\/jkaoms.2014.40.5.206","article-title":"Drug holiday as a prognostic factor of medication-related osteonecrosis of the jaw","volume":"40","author":"Kim","year":"2014","journal-title":"J Korean Assoc Oral Maxillofac Surg."},{"key":"B47","doi-asserted-by":"publisher","first-page":"e03795","DOI":"10.1016\/j.heliyon.2020.e03795","article-title":"Efficacy of a high-dose antiresorptive drug holiday to reduce the risk of medication-related osteonecrosis of the jaw (MRONJ): A systematic review","volume":"6","author":"Ottesen","year":"2020","journal-title":"Heliyon."},{"key":"B48","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.sdentj.2022.01.003","article-title":"Medication-Related Osteonecrosis of the Jaw (MRONJ): a review of pathophysiology, risk factors, preventive measures and treatment strategies","volume":"34","author":"AlRowis","year":"2022","journal-title":"Saudi Dent J."},{"key":"B49","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1111\/j.1600-0765.2010.01306.x","article-title":"Effect of bisphosphonates on human gingival fibroblast production of mediators of osteoclastogenesis: RANKL, osteoprotegerin and interleukin-6","volume":"46","author":"Tipton","year":"2011","journal-title":"J Periodontal Res."},{"key":"B50","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.joms.2016.07.019","article-title":"Osteonecrosis of the jaw in the absence of antiresorptive or antiangiogenic exposure: a series of 6 cases","volume":"75","author":"Aghaloo","year":"2017","journal-title":"J Oral Maxillofac Surg."},{"key":"B51","doi-asserted-by":"publisher","first-page":"e694","DOI":"10.1097\/SCS.0000000000008588","article-title":"Medication-related osteonecrosis of the jaw associated in a patient treated with etanercept","volume":"33","author":"Nisi","year":"2022","journal-title":"J Craniofac Surg"},{"key":"B52","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1111\/odi.12513","article-title":"Immune cellular profile of bisphosphonate-related osteonecrosis of the jaw","volume":"22","author":"Silva","year":"2016","journal-title":"Oral Dis."},{"key":"B53","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1016\/j.pharmthera.2007.10.001","article-title":"Tumor necrosis factor antagonist mechanisms of action: A comprehensive review","volume":"117","author":"Tracey","year":"2008","journal-title":"Pharmacol Ther."},{"key":"B54","doi-asserted-by":"publisher","first-page":"782382","DOI":"10.1155\/2015\/782382","article-title":"The role of IL-1\u03b2 in the bone loss during rheumatic diseases","volume":"2015","author":"Ruscitti","year":"2015","journal-title":"Mediators Inflamm."},{"key":"B55","doi-asserted-by":"publisher","first-page":"606043","DOI":"10.3389\/fimmu.2021.606043","article-title":"The role of the immune response in the development of medication-related osteonecrosis of the jaw","volume":"12","author":"Zhang","year":"2021","journal-title":"Front Immunol."},{"key":"B56","doi-asserted-by":"publisher","first-page":"9739","DOI":"10.3390\/ijms21249739","article-title":"The roles of matrix metalloproteinases and their inhibitors in human diseases","volume":"21","author":"Cabral-Pacheco","year":"2020","journal-title":"Int J Mol Sci"},{"key":"B57","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1016\/j.jmb.2007.06.006","article-title":"RNA-binding protein RBMS3 is expressed in activated hepatic stellate cells and liver fibrosis and increases expression of transcription factor Prx1","volume":"371","author":"Fritz","year":"2007","journal-title":"J Mol Biol."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2023.1164051\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,31]],"date-time":"2023-08-31T16:10:10Z","timestamp":1693498210000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2023.1164051\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,31]]},"references-count":57,"alternative-id":["10.3389\/fmed.2023.1164051"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2023.1164051","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,31]]},"article-number":"1164051"}}